Overview

Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels

Status:
Completed

Trial end date:
2021-06-30

Target enrollment:

Participant gender:

Summary

Evaluation of the activity, safety and patients reported outcome of ADT plus abiraterone, abiraterone plus APALUTAMIDE (a second-generation antiandrogen) or APALUTAMIDE alone in hormone naïve locally advanced or metastatic prostate cancer which ADT was indicated.

Phase:

Phase 2

Details

Lead Sponsor:

Latin American Cooperative Oncology Group

Collaborator:

Janssen Pharmaceuticals

Treatments:

Abiraterone Acetate
Goserelin
Methyltestosterone
Prednisone
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate